Betmiga lowers pricing with PVA, Tazime keeps original price

MOHW finalizes changes in List of Reimbursed Drug

Stivarga 40 mg tablet to be priced at KRW 34,045 from June 1

Reimbursement on Invega and Jurnista still provided until August

Hanmi Pharmaceutical’s bacterial blood infection and meningitis treatment Tazime 2 g injection has been exempted from automatic pricing reduction as its competing item is removed from the tentative reimbursement listing.

 

The price of Astellas Pharma Korea’s blockbuster drug Betmiga PR tablet would be lowered from Mar 1 due to price-volume agreement (PVA) system.

 

Successfully signing risk sharing agreement (RSA), the price of Bayer Korea’s metastatic colorectal cancer and gastrointestinal stromal tumor (GIST) treatment Stivarga 40 mg tablet (regorafenib) would be reduced by 7 percent to 34,045 won, starting from June 1.

 

Janssen Korea’s Invega ER tablet, AbbVie Korea’s Jurnista 4 mg SR tablet and LG Chem’s AspoV Nail Lacquer are to be removed from the reimbursement listing from Mar 1, as the respective companies have voluntarily dropped the item approval.

 

But the reimbursement would be provided until August 31 for the treatment access of patients.

 

Ministry of Health and Welfare (MOHW) finalized the said changes on the List of Reimbursed Drugs and Maximum Reimbursed Price.

 

First, Hanmi Pharmaceutical’s Tazime 2 g injection would maintain the reimbursed price as another listed option was removed from the listing.

 

Korea Prime Pharm’s Tofdin 2 g injection was supposed to be competing against and affecting price of Tazime 2 g injection.

 

The competing injection had applied for tentative reimbursement as it was scheduled to launch on Mar.

 

21.

 

It would have automatically lowered the price of Tazime 2 g injection to 16,400 won per vial from Mar.

 

21.

 

But upon request by Korea Prime Pharm, Tofdin 2 g injection was dropped from the tentative listing and left Tazime 2 g injection with its original listing price.

 

Accordingly, MOHW has decided to keep the existing reimbursed price of 18,082 won per vial for Tazime 2 g injection.

 

Also, Hanwha Pharma’s Muteran syrup, two doses of Seoul Pharma’s Sebron syrup, and two doses of Kolon Pharmaceutical’s Turant syrup would maintain the initial reimbursed pricing as first generic in the class, because no other company has registered a generic in the class for over a year.

 

It would come in effect from Mar.

 

1.

 

Indicated to treat metastatic colorectal cancer, GIST and hepatocellular carcinoma (HCC), Bayer Korea’s Stivarga 40 mg tablet is lowering its price with renewed RSA from June 1.

 

Stivarga 40 mg tablet engaged in renegotiation with National Health Insurance Service (NHIS) and successfully renewed the RSA by lowering the price by 7 percent to 34,045 won.

 

Negotiated with NHIS over PVA, Astellas Pharma Korea would lower the price of 50 mg and 25 mg PR tablets of Betmiga to 712 won and 475 won, respectively, from Mar.

 

1.

 

Due to expanded indication, Takeda Pharmaceuticals Korea is proactively lowering the price of Adcetris injection by 3.6 percent from 3,262,400 won to 3,144,953 won, starting from the beginning of next month.

 

34 items would be automatically unlisted from reimbursement listing as the pharmaceutical company voluntarily withdrew their item licenses.

 

The following items are included among the 34 items; Janssen Korea’s Topamax sprinkle capsule and Invega ER tablet; Abbvie Korea’s Lucrin 3.75 mg depot injection and Jurnista 4 mg SR tablet; LG Chem’s AspoV Nail Lacquer; CTCBIO’s Newtiro tablet, Lastrin tablet, Zetis tablet and Protera 2 mg tablet; Union Korea Pharm’s Union Ofloxacin eye drop; Chem Tech Research Inc.’s Highpure eye drops 0.1%; Binex’ Epinis tablet; Sam Il’s Valsarodin tablet; Cosmax Bio’s Cosvix tablet, Nizamax 150 mg capsule and Cosbamin tablet, Maxtop tablet, Cosrid tablet, Cosverin tablet, Cosulon capsule, Cos 2 mg DR tablet, and Clycin dry syrup; NBK Pharm’s Pendes tablet; and Korea Global Pharm’s Thioctad 200 mg tablet.

 

The drugs above would be removed from the List of Reimbursed Drugs from Mar.

 

1, but the government would continue to provide the reimbursement for the medications until Aug.

 

31 for the sake of patient’s treatment accessibility and predictability.